Novocure Stock Cash And Equivalents

NVCR Stock

USD 19.33 0.15 0.78%

Novocure fundamentals help investors to digest information that contributes to Novocure's financial success or failures. It also enables traders to predict the movement of Novocure Stock. The fundamental analysis module provides a way to measure Novocure's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novocure stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Novocure Company Cash And Equivalents Analysis

Novocure's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current Novocure Cash And Equivalents

948.52 M

Most of Novocure's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novocure is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Novocure Cash And Equivalents Driver Correlations

Understanding the fundamental principles of building solid financial models for Novocure is extremely important. It helps to project a fair market value of Novocure Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Novocure's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novocure's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novocure's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Short Term Investments	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Property Plant Equipment	Long Term Investments	Current Deferred Revenue	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital
Total Assets		0.92	0.96	0.89	-0.8	0.89	0.83	0.92	0.94	0.93	0.83	1.0	0.54	0.77	0.79	0.94	0.92	0.98	0.99	0.87
Total Stockholder Equity	0.92		0.96	0.8	-0.59	0.76	0.8	0.82	0.87	0.81	0.69	0.93	0.28	0.6	0.6	0.87	0.83	0.86	0.92	0.89
Net Tangible Assets	0.96	0.96		0.76	-0.67	0.81	0.74	0.81	0.87	0.83	0.7	0.96	0.38	0.64	0.65	0.85	0.85	0.93	0.94	0.81
Net Debt	0.89	0.8	0.76		-0.71	0.77	0.95	0.86	0.86	0.83	0.75	0.89	0.6	0.76	0.73	0.9	0.8	0.82	0.87	0.92
Retained Earnings	-0.8	-0.59	-0.67	-0.71		-0.93	-0.53	-0.8	-0.86	-0.92	-0.89	-0.78	-0.75	-0.73	-0.88	-0.8	-0.86	-0.85	-0.79	-0.6
Accounts Payable	0.89	0.76	0.81	0.77	-0.93		0.62	0.81	0.96	0.99	0.86	0.88	0.6	0.73	0.74	0.86	0.98	0.92	0.92	0.76
Long Term Debt	0.83	0.8	0.74	0.95	-0.53	0.62		0.8	0.73	0.69	0.66	0.84	0.43	0.69	0.62	0.85	0.67	0.72	0.8	0.93
Net Receivables	0.92	0.82	0.81	0.86	-0.8	0.81	0.8		0.86	0.87	0.92	0.92	0.55	0.84	0.89	0.97	0.82	0.9	0.89	0.82
Short Term Investments	0.94	0.87	0.87	0.86	-0.86	0.96	0.73	0.86		0.98	0.83	0.94	0.56	0.73	0.73	0.9	0.98	0.93	0.97	0.86
Total Liab	0.93	0.81	0.83	0.83	-0.92	0.99	0.69	0.87	0.98		0.89	0.92	0.6	0.75	0.78	0.91	0.99	0.94	0.95	0.82
Short Long Term Debt	0.83	0.69	0.7	0.75	-0.89	0.86	0.66	0.92	0.83	0.89		0.82	0.5	0.74	0.88	0.93	0.83	0.84	0.82	0.74
Total Current Assets	1.0	0.93	0.96	0.89	-0.78	0.88	0.84	0.92	0.94	0.92	0.82		0.53	0.77	0.78	0.94	0.92	0.97	0.99	0.88
Short Term Debt	0.54	0.28	0.38	0.6	-0.75	0.6	0.43	0.55	0.56	0.6	0.5	0.53		0.71	0.72	0.46	0.52	0.55	0.49	0.33
Property Plant Equipment	0.77	0.6	0.64	0.76	-0.73	0.73	0.69	0.84	0.73	0.75	0.74	0.77	0.71		0.78	0.77	0.71	0.74	0.73	0.64
Long Term Investments	0.79	0.6	0.65	0.73	-0.88	0.74	0.62	0.89	0.73	0.78	0.88	0.78	0.72	0.78		0.83	0.69	0.79	0.73	0.59
Current Deferred Revenue	0.94	0.87	0.85	0.9	-0.8	0.86	0.85	0.97	0.9	0.91	0.93	0.94	0.46	0.77	0.83		0.88	0.91	0.94	0.92
Long Term Debt Total	0.92	0.83	0.85	0.8	-0.86	0.98	0.67	0.82	0.98	0.99	0.83	0.92	0.52	0.71	0.69	0.88		0.93	0.96	0.82
Capital Surpluse	0.98	0.86	0.93	0.82	-0.85	0.92	0.72	0.9	0.93	0.94	0.84	0.97	0.55	0.74	0.79	0.91	0.93		0.97	0.79
Net Invested Capital	0.99	0.92	0.94	0.87	-0.79	0.92	0.8	0.89	0.97	0.95	0.82	0.99	0.49	0.73	0.73	0.94	0.96	0.97		0.89
Net Working Capital	0.87	0.89	0.81	0.92	-0.6	0.76	0.93	0.82	0.86	0.82	0.74	0.88	0.33	0.64	0.59	0.92	0.82	0.79	0.89

Click cells to compare fundamentals

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Competition

Predict Novocure

Novocure Cash And Cash Equivalents Changes

Cash And Cash Equivalents Changes

(80.09 Million)

Novocure reported last year Cash And Cash Equivalents Changes of (84.31 Million)

In accordance with the recently published financial statements, Novocure has 948.52 M in Cash And Equivalents. This is 15.55% higher than that of the Health Care Equipment & Supplies sector and 202.11% higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 64.9% higher than that of the company.

Novocure Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novocure's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novocure could also be used in its relative valuation, which is a method of valuing Novocure by comparing valuation metrics of similar companies.

Novocure is currently under evaluation in cash and equivalents category among its peers.

Novocure Current Valuation Drivers

We derive many important indicators used in calculating different scores of Novocure from analyzing Novocure's financial statements. These drivers represent accounts that assess Novocure's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Novocure's important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	17.5B	7.8B	7.7B	1.6B	3.2B	4.2B
Enterprise Value	17.7B	8.1B	8.1B	1.9B	3.1B	4.3B

Novocure ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novocure's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novocure's managers, analysts, and investors.

Environmental

Governance

Social

Novocure Fundamentals

	Return On Equity	-0.47
	Return On Asset	-0.0877
	Profit Margin	(0.28) %
	Operating Margin	(0.39) %
	Current Valuation	1.85 B
	Shares Outstanding	109.92 M
	Shares Owned By Insiders	9.70 %
	Shares Owned By Institutions	84.85 %
	Number Of Shares Shorted	5.2 M
	Price To Earning	721.15 X
	Price To Book	5.90 X
	Price To Sales	3.51 X
	Revenue	605.22 M
	Gross Profit	469.04 M
	EBITDA	(109.58 M)
	Net Income	(168.63 M)
	Cash And Equivalents	948.52 M
	Cash Per Share	9.06 X
	Total Debt	93.13 M
	Debt To Equity	1.31 %
	Current Ratio	8.08 X
	Book Value Per Share	3.32 X
	Cash Flow From Operations	(26.37 M)
	Short Ratio	5.65 X
	Earnings Per Share	(1.56) X
	Price To Earnings To Growth	(0.47) X
	Target Price	35.57
	Number Of Employees	1.49 K
	Beta	0.63
	Market Capitalization	2.12 B
	Total Asset	1.24 B
	Retained Earnings	(1.15 B)
	Working Capital	350.2 M
	Current Asset	293.9 M
	Current Liabilities	28.63 M
	Net Asset	1.24 B

About Novocure Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novocure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novocure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novocure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Additional Tools for Novocure Stock Analysis

When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC